HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Raises Price Target to $8

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $7 to $8.